ProCE Banner Activity


Gastric Cancer: New Strategies, New Therapies, New Hope, Part 1

Podcast Episodes

In this first of 2 episodes on strategies and therapies for treating advanced gastric cancer, an expert discusses the data supporting treatment selection. A case illustrates key takeaways about molecular markers that can impact choice of therapy in gastric cancer, novel and emerging treatments, and prevention and management treatment-related toxicities.

To access episode 2, click here.

Physician Assistants: maximum of 0.50 hours of AAPA Category 1 CME credits Registered Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacology credit

Released: February 25, 2022

Expiration: February 24, 2023

No longer available for credit.



David H. Ilson

David H. Ilson, MD, PhD

Department of Medicine
Weill Cornell Medical College
Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York


This program is cosupported by educational grants from Bristol-Myers Squibb; Eisai; and Merck Sharp & Dohme Corp.

This activity is supported by educational grants from Bristol-Myers Squibb and Merck Sharp & Dohme Corp.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Identify molecular markers that can impact choice of therapy in gastric cancer

  • Use clinical trial evidence and guidance recommendations to identify the role of novel and emerging treatment for advanced gastric cancer

  • Implement strategies to prevent and manage toxicities associated with novel treatment strategies


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.

Ms Moench: fees for non-CME/CE services: Gilead Sciences, Inc.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose, except Ms Moench as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. Listen to the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the post-test and evaluation form

The estimated time to complete this activity is 0.50 hours.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 100%.

Release date: February 25, 2022
Expiration date: February 24, 2023




The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 0.50, which includes 0.50 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until February 24, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA Course Advisor: Susan Moench, PhD, PA-C, Edison, New Jersey

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.